The CLL2-GIVe study assesses the response and tolerability of the triple combination comprising obinutuzumab, ibrutinib, and venetoclax (GIVe regimen) in forty-one previously untreated high-risk CLL patients with del(17p) and/or TP53 mutation. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.